J M S Bartlett
Overview
Explore the profile of J M S Bartlett including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
59
Citations
1818
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Berman D, Lee A, Lesurf R, Patel P, Ebrahimizadeh W, Bayani J, et al.
J Urol
. 2023 May;
210(2):257-271.
PMID: 37126232
Purpose: Latent grade group ≥2 prostate cancer can impact the performance of active surveillance protocols. To date, molecular biomarkers for active surveillance have relied solely on RNA or protein. We...
2.
Bartlett J, Sgroi D, Treuner K, Zhang Y, Ahmed I, Piper T, et al.
Ann Oncol
. 2019 Sep;
30(11):1776-1783.
PMID: 31504126
Background: Extending the duration of adjuvant endocrine therapy reduces the risk of recurrence in a subset of women with early-stage hormone receptor-positive (HR+) breast cancer. Validated predictive biomarkers of endocrine...
3.
Blanchette P, Desautels D, Pond G, Bartlett J, Nofech-Mozes S, Yaffe M, et al.
Breast Cancer Res Treat
. 2018 Mar;
170(1):169-177.
PMID: 29520532
Purpose: We have limited capability to predict survival among patients treated for metastatic HER2-positive breast cancer. Further research is warranted to identify significant prognostic and predictive factors. Methods: We identified...
4.
Cheang M, Bliss J, Viale G, Speirs V, Palmieri C, Shaaban A, et al.
Breast Cancer Res Treat
. 2017 Nov;
168(1):169-178.
PMID: 29177605
Background: Intergroup Exemestane Study (IES) was a randomised study that showed a survival benefit of switching adjuvant endocrine therapy after 2-3 years from tamoxifen to exemestane. This PathIES aimed to...
5.
Cardoso F, Bartlett J, Slaets L, van Deurzen C, van Leeuwen-Stok E, Porter P, et al.
Ann Oncol
. 2017 Nov;
29(2):405-417.
PMID: 29092024
Background: Male breast cancer (BC) is rare, managed by extrapolation from female BC. The International Male BC Program aims to better characterize and manage this disease. We report the results...
6.
Ali H, Dariush A, Thomas J, Provenzano E, Dunn J, Hiller L, et al.
Ann Oncol
. 2017 May;
28(8):1832-1835.
PMID: 28525534
Background: We have previously shown lymphocyte density, measured using computational pathology, is associated with pathological complete response (pCR) in breast cancer. The clinical validity of this finding in independent studies,...
7.
Earl H, Hiller L, Dunn J, Blenkinsop C, Grybowicz L, Vallier A, et al.
Ann Oncol
. 2017 May;
28(8):1817-1824.
PMID: 28459938
Background: The ARTemis trial previously reported that addition of neoadjuvant bevacizumab (Bev) to docetaxel (D) followed by fluorouracil, epirubicin and cyclophosphamide (D-FEC) in HER2 negative breast cancer improved the pathological...
8.
Tryfonidis K, Marreaud S, Khaled H, de Valk B, Vermorken J, Welnicka-Jaskiewicz M, et al.
Breast Cancer Res Treat
. 2017 Mar;
163(3):507-515.
PMID: 28324265
Purpose: Cardiotoxicity is a side effect of trastuzumab. We assessed efficacy and cardiac safety of CMF with trastuzumab (CMF+T) in HER2-positive metastatic breast cancer patients (MBC). Methods: In this phase...
9.
Pinder S, Campbell A, Bartlett J, Marshall A, Allen D, Falzon M, et al.
Br J Cancer
. 2017 Feb;
116(7):859-863.
PMID: 28222072
Background: There is limited data on results of central re-testing of samples from patients with invasive breast cancer categorised in their local hospital laboratories as oestrogen receptor (ER) positive and...
10.
Thomas J, Hanby A, Russell N, van Tienhoven G, Riddle K, Anderson N, et al.
Breast Cancer Res Treat
. 2017 Feb;
163(1):63-69.
PMID: 28190252
Introduction: SUPREMO is a phase 3 randomised trial evaluating radiotherapy post-mastectomy for intermediate-risk breast cancer. 1688 patients were enrolled from 16 countries between 2006 and 2013. We report the results...